First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy

20156 citationsJournal Article

Authors

Good health and well-being

Published in: Cancer Chemotherapy and Pharmacology

Volume 75, Issue 5, pp. 929-939

Field-Weighted Citation Impact: 0.29